Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50929
Name mucosal melanoma
Definition A melanoma that has_material_basis_in melanocytes located_in mucosal membranes lining the respiratory, gastrointestinal and urogenital tract.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer melanoma mucosal melanoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KIT C443S Imatinib mucosal melanoma sensitive detail...
Unknown unknown Toripalimab mucosal melanoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02748564 Phase II Aldesleukin + Pembrolizumab Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Active, not recruiting USA 0
NCT02818023 Phase I Cobimetinib + Pembrolizumab + Vemurafenib Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma Active, not recruiting USA 0
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT02978443 Phase II Ipilimumab + Nivolumab A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Active, not recruiting USA 0
NCT03220009 Phase II Ipilimumab + Nivolumab Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn USA 0
NCT03235245 Phase II Binimetinib + Encorafenib Ipilimumab + Nivolumab Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) Recruiting 8
NCT03241186 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma Recruiting USA 0
NCT03313206 Phase II Pembrolizumab Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ) Recruiting 1
NCT03817125 Phase I Nivolumab + SER-401 Vancomycin Nivolumab Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) Active, not recruiting USA 0
NCT03875079 Phase I Pembrolizumab + RO6874281 A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-A, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma Active, not recruiting USA | CAN 5
NCT03991741 Phase I Aldesleukin Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors Recruiting USA 0
NCT04042506 Phase II Nivolumab SBRT as a Vaccination for Metastatic Melanoma Withdrawn USA 0
NCT04139902 Phase II Dostarlimab-gxly + TSR-022 Dostarlimab-gxly PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) Recruiting USA 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04318717 Phase Ib/II Pembrolizumab Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma Recruiting USA 0
NCT04493203 Phase II Axitinib + Nivolumab Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma Recruiting USA 0
NCT04551352 Phase I RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Recruiting USA | CAN 5
NCT04577807 Phase II PVSRIPO + unspecified PD-1 antibody PVSRIPO PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma Recruiting USA 0